Claims
- 1. An imidazopyridine compound of the formula: ##STR5## wherein R.sup.1 is lower alkynyl or lower alkynyloxy(lower)alkyl,
- R.sup.2 is lower alkyl, and
- R.sup.3 is mono(or di or tri)phenyl(lower)alkyl substituted by lower alkoxy, lower alkylthio, nitro or lower alkanesulfonyl, mono(or di or tri)phenyl(lower)alkyl substituted by nitro and one or two additional substituent(s) selected from nitro and lower alkyl, heterocyclic(lower)alkyl in which the heterocyclic moiety is selected from thienyl, furyl, pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl or triazinyl, or said heterocyclic(lower)alkyl substituted by at least one substituent selected from the group consisting of lower alkyl, lower alkoxy, and lower alkanamido, and a pharmaceutically acceptable salt thereof.
- 2. A compound of claim 1, wherein
- R.sup.3 is phenyl(lower)alkyl substituted by lower alkoxy, lower alkylthio, nitro or lower alkanesulfonyl.
- 3. A compound of claim 2, wherein
- R.sup.3 is benzyl substituted by methoxy, methylthio, nitro or mesyl.
- 4. A compound of claim 3, which is selected from a group consisting of:
- 8-(2-methoxybenzyloxy)-2-methyl-3-(2-propynyl)imidazo[1,2-a]pyridine,
- 2-methyl-8-(2-methylthiobenzyloxy)-3-(2-propynyl)imidazo[1,2-a]pyridine,
- 2-methyl-8-(2-nitrobenzyloxy)-3-(2-propynyl)imidazo[1,2-a]pyridine,
- 8-(2-mesylbenzyloxy)-2-methyl-3-(2-propynyl)imidazo[1,2-a]pyridine,
- 8-(2-methoxybenzyloxy)-2-methyl-3-(2-propynyloxymethyl)imidazo[1,2-a]pyridine, and
- 2-methyl-8-(2-nitrobenzyloxy)-3-(2-propynyloxymethyl)imidazo[1,2-a]pyridine.
- 5. A compound of claim 4, which is
- 8-(2-methoxybenzyloxy)-2-methyl-3-(2-propynyl)imidazo[1,2-a]pyridine.
- 6. A compound of claim 4, which is
- 8-(2-methoxybenzyloxy)-2-methyl-3-(2-propynyloxymethyl)imidazo[1,2-a]pyridine.
- 7. A compound of claim 1, wherein
- R.sup.3 is phenyl(lower)alkyl substituted by nitro and one or two additional substituent(s) selected from nitro and lower alkyl.
- 8. A compound of claim 7, wherein
- R.sup.3 is benzyl substituted by nitro and one or two additional substituent(s) selected from nitro and methyl.
- 9. A compound of claim 8, which is selected from a group consisting of:
- 8-(2,6-dimethyl-3-nitrobenzyloxy)-2-methyl-3-(2-propynyl)imidazo[1,2-a]pyridine,
- 2-methyl-8-(2-methyl-6-nitrobenzyloxy)-3-(2-propynyl)imidazo[1,2-a]pyridine
- 2-methyl-8-(2-methyl-3-nitrobenzyloxy)-3-(2-propynyl)imidazo[1,2-a]pyridine, and
- 2-methyl-8-(2-methyl-5-nitrobenzyloxy)-3-(2-propynyl)imidazo[1,2-a]pyridine.
- 10. A compound of claim 1, wherein
- R.sup.3 is 3 to 7 membered heteromonocyclic(lower)alkyl in which the heterocyclic moiety is selected from thienyl, furyl, pyrrolyl, pyrazolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl or triazinyl, or is said heterocyclic(lower)alkyl substituted by at least one substituent selected from the group consisting of lower alkyl, lower alkoxy and lower alkanamido.
- 11. A compound of claim 10, wherein
- R.sup.3 is thienyl substituted by methyl, thiazolyl having acetamido or pyridyl which is unsubstituted or is substituted by methyl or methoxy.
- 12. A compound of claim 11, which is selected from a group consisting of:
- 2-methyl-8-(3-methyl-2-thienylmethoxy)-3-(2-propynyl)imidazo[1,2-a]pyridine
- 2-methyl-3-(2-propynyl)-8-(3-pyridylmethoxy)imidazo[1,2-a]pyridine,
- 2-methyl-8-(3-methyl-4-pyridylmethoxy)-3-(2-propynyl)imidazo[1,2-a]pyridine
- 2-methyl-8-(2-methyl-3-pyridylmethoxy)-3-(2-propynyl)imidazo[1,2-a]pyridine
- 2-methyl-8-(3-methyl-2-pyridylmethoxy)-3-(2-propynyl)imidazo[1,2-a]pyridine
- 8-(2-acetamidothiazol-4-ylmethoxy)-2-methyl-3-(2-propynyl)imidazo[1,2-a]pyridine,
- 8-(3,5-dimethyl-4-methoxy-2-pyridylmethoxy)-2-methyl-3-(2-propynyl)imidazo[1,2-a]pyridine, and
- 2-methyl-8-(4-methyl-3-pyridylmethoxy)-3-(2-propynyl)imidazo[1,2-a]pyridine.
- 13. A pharmaceutical composition which comprises, as an active ingredient, an antiulcerative effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
- 14. A method for the treatment of a human or animal patient subject to ulcer which comprises administering an antiulcerative effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof to said human or animal patient.
Priority Claims (2)
Number |
Date |
Country |
Kind |
8530878 |
Dec 1985 |
GBX |
|
8627736 |
Nov 1986 |
GBX |
|
Parent Case Info
This application is a continuation-in-part of application Ser. No. 865,331, filed May 21, 1986.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4450164 |
Bristol et al. |
May 1984 |
|
Foreign Referenced Citations (1)
Number |
Date |
Country |
33094 |
Aug 1981 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
865331 |
May 1986 |
|